IL140623A - Aralkyl and aralkylidene heterocyclic lactams and imides - Google Patents

Aralkyl and aralkylidene heterocyclic lactams and imides

Info

Publication number
IL140623A
IL140623A IL14062397A IL14062397A IL140623A IL 140623 A IL140623 A IL 140623A IL 14062397 A IL14062397 A IL 14062397A IL 14062397 A IL14062397 A IL 14062397A IL 140623 A IL140623 A IL 140623A
Authority
IL
Israel
Prior art keywords
imides
aralkyl
heterocyclic lactams
aralkylidene heterocyclic
aralkylidene
Prior art date
Application number
IL14062397A
Other languages
English (en)
Other versions
IL140623A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL140623A0 publication Critical patent/IL140623A0/xx
Publication of IL140623A publication Critical patent/IL140623A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL14062397A 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides IL140623A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2711196P 1996-09-30 1996-09-30
IL12904597A IL129045A (en) 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides and pharmaceutical compositions comprising them
PCT/IB1997/001062 WO1998014433A1 (en) 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides

Publications (2)

Publication Number Publication Date
IL140623A0 IL140623A0 (en) 2002-02-10
IL140623A true IL140623A (en) 2005-03-20

Family

ID=21835752

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14062397A IL140623A (en) 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides
IL12904597A IL129045A (en) 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides and pharmaceutical compositions comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12904597A IL129045A (en) 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides and pharmaceutical compositions comprising them

Country Status (46)

Country Link
US (6) US6380186B1 (es)
EP (1) EP0929528B1 (es)
JP (1) JP3121355B2 (es)
KR (2) KR100323167B1 (es)
CN (2) CN1239497C (es)
AP (1) AP769A (es)
AR (1) AR008861A1 (es)
AT (1) ATE245630T1 (es)
AU (1) AU732451B2 (es)
BG (1) BG64484B1 (es)
BR (1) BR9713239A (es)
CA (1) CA2266107C (es)
CO (1) CO4650135A1 (es)
CZ (1) CZ295141B6 (es)
DE (1) DE69723711T2 (es)
DK (1) DK0929528T3 (es)
DZ (1) DZ2321A1 (es)
EA (1) EA002157B1 (es)
ES (1) ES2202634T3 (es)
GT (1) GT199700107A (es)
HK (1) HK1022313A1 (es)
HN (1) HN1997000135A (es)
HR (1) HRP970540B1 (es)
ID (1) ID19833A (es)
IL (2) IL140623A (es)
IS (1) IS4985A (es)
MA (1) MA26443A1 (es)
MY (1) MY125749A (es)
NO (1) NO313192B1 (es)
NZ (1) NZ334215A (es)
OA (1) OA11002A (es)
PA (1) PA8439101A1 (es)
PE (1) PE2799A1 (es)
PL (1) PL196005B1 (es)
PT (1) PT929528E (es)
RS (1) RS49699B (es)
SA (2) SA97180449B1 (es)
SI (1) SI0929528T1 (es)
SK (1) SK284704B6 (es)
TN (1) TNSN97161A1 (es)
TR (1) TR199900660T2 (es)
TW (1) TW491842B (es)
UA (1) UA56185C2 (es)
UY (1) UY24730A1 (es)
WO (1) WO1998014433A1 (es)
ZA (1) ZA978703B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
DE69919436T2 (de) 1998-04-16 2005-09-15 Pfizer Products Inc., Groton N-Acyl und N-Aroyl Aralkylamide
CA2350597A1 (en) * 1998-12-02 2000-06-08 Barbara Ann Foster Methods and compositions for restoring conformational stability of a protein of the p53 family
ATE277025T1 (de) * 1999-03-30 2004-10-15 Pfizer Prod Inc Verfahren zur herstellung von cyclischen thioamiden
DE10022661A1 (de) * 2000-05-10 2001-11-15 Clariant Gmbh Ortho-substituierte Benzaldehyde, Verfahren zu ihrer Herstellung und ihre Verwendung
UA76130C2 (en) 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
AU2002305123B2 (en) * 2001-03-30 2006-10-05 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
EP1746091A1 (en) * 2001-08-30 2007-01-24 Pfizer Products Inc. Process for the preparation of 2-substituted 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one citrate
EP1288208B1 (en) 2001-08-30 2006-07-12 Pfizer Products Inc. Process for the preparation of 2-(4-Alkyl-1-Piperazinyl)-Benzaldehyde and -Benzylidenyl compounds by Nucleophilc Aromatic Substitution of 2-Fluorobenzaldehyde with 4-Alkyl-1-Piperazine in Water as Solvent
US8575169B2 (en) 2001-10-29 2013-11-05 Versi Group, Llc Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
BR0214780A (pt) * 2001-12-07 2004-11-09 Pfizer Prod Inc Sal de ácido cìtrico de um composto terapêutico e composições farmacêuticas deste
PL376147A1 (en) * 2002-09-30 2005-12-27 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
EP1546109A4 (en) * 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
WO2005053701A1 (en) * 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
ES2347152T3 (es) * 2003-11-26 2010-10-26 Pfizer Products Inc. Derivados de aminopirazol como inhibidores de gsk-3.
BRPI0417709A (pt) * 2003-12-15 2007-03-20 Pfizer Prod Inc lactamas heterocìclicas de aralquilidemo e aralquila e imidas
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
EP1737466A1 (en) * 2004-01-29 2007-01-03 Pfizer Products Inc. COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS
JP4880583B2 (ja) 2004-03-17 2012-02-22 ファイザー・プロダクツ・インク 新規なベンジル（ベンジリデン）−ラクタム誘導体
MXPA06012505A (es) 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
WO2005113526A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
EP1753745A2 (en) * 2004-05-21 2007-02-21 Pfizer Products Inc. Pyrazinylmethyl lactam derivatives
WO2006048727A1 (en) * 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
WO2006106416A1 (en) * 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
WO2007026219A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
WO2007026224A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. 5-ht1b antagonist composition for depression, anxiety and cognition
WO2007057742A2 (en) * 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
AU2009228307A1 (en) * 2008-03-25 2009-10-01 The Regents Of The University Of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
EP2763992B9 (en) * 2011-10-03 2016-08-24 Euroscreen S.A. Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, and methods for use in nk-3 receptor mediated disorders
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
DE102013019618B4 (de) * 2013-11-25 2024-08-29 Avlen Georges Tri- und Tetracyclische Verbindungen zur Behandlung von Inkontinenz
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110054597B (zh) * 2019-04-17 2022-11-08 温州大学 一种无金属催化剂条件下合成的噻唑烷-4-酮衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
HU199134B (en) 1987-12-14 1990-01-29 Richter Gedeon Vegyeszet Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
DE4119757A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
AU6391894A (en) * 1993-03-16 1994-10-11 Pfizer Inc. Naphthalene derivatives
US5556841A (en) * 1994-02-04 1996-09-17 Santen Pharmaceutical Co., Ltd. Thiazine or thiomorpholine derivatives
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
ES2169131T3 (es) * 1994-06-29 2002-07-01 Pfizer Derivados de aril y heteroaril alcoxinaftaleno.
JP3852787B2 (ja) 1995-06-01 2006-12-06 久光製薬株式会社 チオモルホリン誘導体
EP0779282A1 (en) * 1995-12-14 1997-06-18 Eli Lilly And Company Thiomorpholinone compounds for treating multiple sclerosis
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування

Also Published As

Publication number Publication date
JP3121355B2 (ja) 2000-12-25
US20020091118A1 (en) 2002-07-11
ID19833A (id) 1998-08-06
US6627627B2 (en) 2003-09-30
TW491842B (en) 2002-06-21
AP769A (en) 1999-09-30
TR199900660T2 (xx) 1999-07-21
CZ107199A3 (cs) 2000-05-17
US20020147194A1 (en) 2002-10-10
HRP970540B1 (en) 2002-08-31
US20020091119A1 (en) 2002-07-11
OA11002A (en) 2001-11-06
TNSN97161A1 (fr) 2005-03-15
IL140623A0 (en) 2002-02-10
CZ295141B6 (cs) 2005-05-18
RS49699B (sr) 2007-12-31
SK41099A3 (en) 2000-09-12
CO4650135A1 (es) 1998-09-03
JP2000503679A (ja) 2000-03-28
ATE245630T1 (de) 2003-08-15
SA05260293B1 (ar) 2006-04-18
NO991525D0 (no) 1999-03-29
AP9701107A0 (en) 1997-10-31
SK284704B6 (sk) 2005-09-08
AR008861A1 (es) 2000-02-23
CA2266107A1 (en) 1998-04-09
HK1022313A1 (en) 2000-08-04
KR20000048731A (ko) 2000-07-25
SI0929528T1 (en) 2003-10-31
MA26443A1 (fr) 2004-12-20
US20020072519A1 (en) 2002-06-13
UA56185C2 (uk) 2003-05-15
US6472388B2 (en) 2002-10-29
US6921760B2 (en) 2005-07-26
AU3951497A (en) 1998-04-24
HN1997000135A (es) 1998-01-28
NO313192B1 (no) 2002-08-26
UY24730A1 (es) 2000-09-29
SA97180449A (ar) 2005-12-03
YU16899A (sh) 2002-03-18
PL196005B1 (pl) 2007-11-30
CN1329002A (zh) 2002-01-02
ZA978703B (en) 1999-03-30
AU732451B2 (en) 2001-04-26
WO1998014433A1 (en) 1998-04-09
MY125749A (en) 2006-08-30
CN1093123C (zh) 2002-10-23
PT929528E (pt) 2003-12-31
GT199700107A (es) 1999-03-23
IS4985A (is) 1999-02-26
DE69723711D1 (de) 2003-08-28
BG103297A (en) 1999-11-30
DK0929528T3 (da) 2003-10-06
ES2202634T3 (es) 2004-04-01
KR100323167B1 (ko) 2002-02-04
HRP970540A2 (en) 1998-08-31
DZ2321A1 (fr) 2002-12-28
BR9713239A (pt) 2000-04-04
IL129045A0 (en) 2000-02-17
CN1231661A (zh) 1999-10-13
PE2799A1 (es) 1999-02-04
NO991525L (no) 1999-05-28
KR100346620B1 (ko) 2002-07-26
US20020091117A1 (en) 2002-07-11
EA002157B1 (ru) 2001-12-24
US6403592B1 (en) 2002-06-11
IL129045A (en) 2005-09-25
SA97180449B1 (ar) 2005-12-21
EA199900242A1 (ru) 1999-08-26
DE69723711T2 (de) 2004-02-05
EP0929528A1 (en) 1999-07-21
BG64484B1 (bg) 2005-04-30
US6562813B2 (en) 2003-05-13
NZ334215A (en) 2000-09-29
PA8439101A1 (es) 2000-05-24
PL332629A1 (en) 1999-09-27
CN1239497C (zh) 2006-02-01
US6380186B1 (en) 2002-04-30
CA2266107C (en) 2002-12-03
EP0929528B1 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
ZA978703B (en) Aralkyl and aralkylidene heterocyclic lactams and imides
AP9700955A0 (en) Lactam derivatives
PL332183A1 (en) Heterocyclic esters and amides
PL332777A1 (en) N-substituted 2-cyanopyrolydines
ZA956869B (en) Novel N-substituted naphthofused lactams
IL130223A0 (en) Novel heterocyclic substituted pyrrolidine amide derivatives
ZA9510305B (en) Heterocyclic amides
GB9405533D0 (en) Heterocyclic derivatives
GB9623283D0 (en) Heterocyclic derivatives
SI0946548T1 (en) Novel heterocyclic substituted pyrrolidine amide derivatives
GB9602145D0 (en) Heterocyclic derivatives
GB9602144D0 (en) Heterocyclic derivatives
GB9722377D0 (en) Heterocyclic derivatives
GB9626857D0 (en) Heterocyclic derivatives
GB9604918D0 (en) Amide derivatives
GB9416084D0 (en) Lactams
SI0937040T1 (en) N-substituted 2-cyanopyrrolidines
GB9425971D0 (en) Heterocyclic arylacetamides
GB9421550D0 (en) Heterocyclic derivative
GB9407433D0 (en) Heterocyclic derivatives
GB9419339D0 (en) Heterocyclic derivatives
GB9402127D0 (en) Heterocyclic derivatives
GB9407431D0 (en) Heterocyclic derivatives
GB9419524D0 (en) Heterocyclic derivatives
GB9419343D0 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees